Digest Network Come funziona
Network
/
Società
Ge
Non verificato

Genentech

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

95 comunicati stampa

Guarda tutti i comunicati
10/09/2026
Industria
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Medicina - Varie
U.S. FDA Grants Priority Review for Genentech’s Enspryng for MOGAD, an Autoimmune Disease With No Approved Treatments
Fonte
Genentech
Emittente
Business Wire
1.00
0
20/08/2026
Industria
Biotecnologia
Farmaceutica
Salute
Genentech Announces Manufacturing Expansion in Hillsboro, Oregon
Fonte
Genentech
Emittente
Business Wire
1.00
0
18/08/2026
Industria
Salute
Mercato Immobiliare
Tecnologia delle costruzioni
Farmaceutica
Biotecnologia
Genentech Marks Topping out Milestone for New Holly Springs, North Carolina Manufacturing Facility
Fonte
Genentech
Emittente
Business Wire
1.00
0
15/07/2026
Industria
Scienza
Igiene alimentare
Biotecnologia
Medicina - Varie
Sanità
Farmaceutica
Salute
Oncologia
FDA Grants Priority Review to Genentech’s Gazyva for Adults With Primary Membranous Nephropathy
Fonte
Genentech
Emittente
Business Wire
1.00
0
07/07/2026
Biotecnologia
Farmaceutica
Salute
Industria
Genentech and Roche Present New Data in Alzheimer’s Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAIC
Fonte
Genentech
Emittente
Business Wire
1.00
0
02/07/2026
Oncologia
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Industria
Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer
Fonte
Genentech
Emittente
Business Wire
1.00
0
30/06/2026
Industria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Ottica
FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
Fonte
Genentech
Emittente
Business Wire
1.00
0
18/06/2026
Industria
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma
Fonte
Genentech
Emittente
Business Wire
1.00
0
11/06/2026
Industria
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer
Fonte
Genentech
Emittente
Business Wire
1.00
0
02/06/2026
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting
Fonte
Genentech
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0